Acute Decompensated Heart Failure (ADHF) | Norton Healthcare

Indication: Acute Decompensated Heart Failure (ADHF)

A multicenter, randomized, double-blind, double-dummy, parallel group, active controlled 8-week study to evaluate the effect of sacubitril/valsartan (LCZ696) versus valsartan on changes in NT-proBNP and safety and tolerability of in-hospital initiation of LCZ696 compared to valsartan in HFpEF patients with acute decompensated heart failure (ADHF) who have been stabilized during hospitalization (PARAGLIDE)

HFpEF (Preserved Ejection Fraction) Patients

Drug Study

Principal Investigator: John Harris, M.D.
Norton Heart & Vascular Institute

Sponsor: Novartis Pharmaceuticals Corp

Email for more information: CVResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.